Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to speed on key events from the week. For those of you interested to read a bit more, we provide links to the source articles.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
BowTiedBiotech
Weekly Biotech Summary
Week of July 27, 2026
Market Snapshot
For the week, the public indexes were UP, with the S&P +1.0% & DOW moving +1.0%. For the year both remain UP +9.2% and +8.5% respectively. The XBI (the biotech index) comes in DOWN -2.3% for the week and remains +21.1% for the year.
This week in biotech saw a mix of clinical, regulatory, and financial developments. Novo Nordisk’s high-profile Phase 3 failure in cardiovascular disease and Alnylam’s revenue guidance cut weighed on sector sentiment. Meanwhile, Replimune secured a positive FDA advisory committee vote for its melanoma therapy, and significant investments and partnerships were announced, including Lilly and Resilience’s $750M manufacturing expansion and J&J’s option to acquire Sail Biomedicines. Regulatory scrutiny also increased, with the FTC suing Hims & Hers over alleged privacy violations.
Clinical Data
Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
What happened
Novo Nordisk’s IL-6 inhibitor ziltivekimab did not reduce major adverse cardiovascular events in a Phase 3 trial involving patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The failure led to a sharp drop in Novo’s share price and affected other companies in the cardiometabolic space.
Why it matters
The result challenges the strategy of targeting inflammation to reduce cardiovascular risk and impacts Novo’s efforts to differentiate itself in the competitive cardiometabolic market. The outcome also had a ripple effect on sector valuations and raises questions about the future of similar approaches.
Regulatory
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
What happened
Replimune received a positive 10-3 vote from an FDA advisory committee for its melanoma immunotherapy RP1, despite concerns over trial design and data interpretation. The committee acknowledged efficacy signals but noted the need for better-defined criteria in future studies.
Why it matters
The vote positions RP1 for potential FDA approval, offering a new option for patients with advanced melanoma who have progressed after prior therapies. It also highlights ongoing challenges in evaluating novel immunotherapies and the importance of robust trial design.
M&A/Licensing
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
What happened
Johnson & Johnson secured an option to acquire Sail Biomedicines, a Flagship Pioneering-backed startup, for up to $2.6 billion. The deal reflects J&J’s interest in next-generation CAR-T technologies, particularly for autoimmune conditions.
Why it matters
This move underscores major pharmaceutical companies’ growing focus on innovative cell therapies and their potential to address a broader range of diseases beyond oncology.
Financing/Manufacturing
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
What happened
Eli Lilly and Resilience announced a $750 million investment to expand U.S. manufacturing capacity for Lilly’s KwikPen injectable device, used for diabetes and obesity medicines. The expansion will create at least 400 jobs in the Cincinnati area and aims to meet rising demand.
Why it matters
The investment addresses critical supply chain needs in the rapidly growing diabetes and obesity drug markets, supporting Lilly’s ability to scale production and maintain competitiveness.
Business/Financial
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
What happened
Alnylam reduced its full-year revenue guidance for its transthyretin (TTR) franchise, leading to a $10.8 billion drop in market capitalization. The company reported lower-than-expected sales for its TTR therapies and missed analyst expectations.
Why it matters
The guidance cut raises concerns about the growth prospects of Alnylam’s TTR portfolio and may affect investor confidence in the RNAi sector. It also highlights the challenges of meeting market expectations in a competitive therapeutic area.
Financing/M&A
Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers
What happened
Caldera Therapeutics and Vidya Therapeutics collectively raised $478 million through reverse mergers with Nasdaq-listed companies, enabling both to access public markets and secure significant private financing.
Why it matters
These transactions exemplify the trend of private biotechs using alternative routes to go public, reflecting ongoing investor interest and the search for capital outside traditional IPOs.
Clinical Data/Business
Moderna maintains 10% growth target despite Phase 3 norovirus miss
What happened
Moderna’s norovirus vaccine candidate failed to meet statistical significance in a Phase 3 interim analysis, but the company maintained its growth targets due to strong ex-U.S. vaccine sales and a recent positive FDA advisory committee decision for its flu vaccine.
Why it matters
The outcome demonstrates Moderna’s resilience in its vaccine pipeline and ability to offset clinical setbacks with commercial performance, while also highlighting the challenges of vaccine development.
Business/Clinical Data
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
What happened
Bristol Myers Squibb reported strong second-quarter earnings and raised its annual outlook, but the news was tempered by delays in key Phase 3 data for its neuropsychology drug Cobenfy and a partnered heart disease candidate.
Why it matters
While financial performance was strong, the delays in pivotal data introduce uncertainty around BMS’s near-term pipeline and highlight the operational challenges of large clinical programs.
Partnership/Drug Development
AbCellera, Vertex partner on next-gen T-cell engagers
What happened
AbCellera and Vertex announced a partnership to develop next-generation T-cell engagers, expanding Vertex’s pipeline beyond its core cystic fibrosis business.
Why it matters
The collaboration reflects the industry’s growing interest in novel immunotherapies and the strategic efforts of established companies to diversify their portfolios.
Regulatory/Legal
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
What happened
The Federal Trade Commission filed a lawsuit against telehealth company Hims & Hers, alleging illegal sharing of patient health data with advertisers and deceptive billing practices. Hims & Hers has denied the allegations.
Why it matters
The case highlights increasing regulatory scrutiny of digital health companies, particularly regarding patient privacy and business practices, and may influence future oversight in the sector.
Thank you for reading BowTiedBiotech. Help us grow our community and earn FREE subscription to BowtiedBiotech - sharing is caring!
CONCLUSION
There you have it, another week of your Weekly Biotech News Fix. We hope you enjoyed it, please drop a comment with any feedback you may have.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
SUBSCRIBE TO PODCAST HERE:
Sundays and Mondays are under the paid umbrella, everything else is FREE. It is $11.99/month and we encourage you to support our efforts. It keeps us motivated to keep producing the hybrid science and business biotech focused content you will not find anywhere else all in the same place.
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Epoch 42 - A Trojan Horse Enters With MASSIVE Biotech Implications
Shaky Public Markets but Innovative Science Continues to Attract Capital
This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.